In a cohort of 640 advanced non-small cell lung cancer (NSCLC) patients, those receiving ≥10 mg of prednisone equivalent within 30 days of starting anti-PDL-1 therapy had worse progression-free survival and overall survival [91]. Here, CD274 is linked to non-small cell lung carcinoma.